Central Pharmaceutical Joint Stock Company No3 (HNX: DP3)
57,300
-200 (-0.35%)
At close: Feb 4, 2025
HNX:DP3 Balance Sheet
Financials in millions VND. Fiscal year is January - December.
Millions VND. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Cash & Equivalents | 13,706 | 5,375 | 21,106 | 24,727 | 40,918 | Upgrade
|
Short-Term Investments | 327,987 | 301,000 | 185,378 | 137,000 | 120,000 | Upgrade
|
Cash & Short-Term Investments | 341,693 | 306,375 | 206,484 | 161,727 | 160,918 | Upgrade
|
Cash Growth | 11.53% | 48.38% | 27.67% | 0.50% | 0.88% | Upgrade
|
Accounts Receivable | 34,817 | 17,061 | 26,898 | 20,857 | 23,940 | Upgrade
|
Other Receivables | 4,604 | 5,857 | 1,758 | 318.51 | 1,988 | Upgrade
|
Receivables | 39,421 | 22,918 | 28,656 | 21,175 | 25,928 | Upgrade
|
Inventory | 43,925 | 52,332 | 69,835 | 67,159 | 56,385 | Upgrade
|
Prepaid Expenses | 222.42 | 247.03 | 49.57 | 334.52 | 48.83 | Upgrade
|
Other Current Assets | 8,065 | 1,880 | 5,161 | 5,050 | 11,531 | Upgrade
|
Total Current Assets | 433,326 | 383,752 | 310,186 | 255,446 | 254,811 | Upgrade
|
Property, Plant & Equipment | 139,947 | 131,247 | 154,414 | 145,838 | 142,492 | Upgrade
|
Other Intangible Assets | - | 20,281 | 6,514 | 6,594 | 5,814 | Upgrade
|
Other Long-Term Assets | 34,504 | 35,346 | 36,755 | 37,626 | 38,242 | Upgrade
|
Total Assets | 607,777 | 570,626 | 507,868 | 445,504 | 441,359 | Upgrade
|
Accounts Payable | 7,642 | 15,695 | 18,474 | 19,499 | 23,880 | Upgrade
|
Accrued Expenses | 63,036 | 58,681 | 50,742 | 44,398 | 41,568 | Upgrade
|
Short-Term Debt | - | 6,800 | 5,230 | 3,528 | 5,378 | Upgrade
|
Current Income Taxes Payable | 14,006 | 14,898 | 10,594 | 8,084 | 12,546 | Upgrade
|
Other Current Liabilities | 4,212 | 5,105 | 5,378 | 3,746 | 11,539 | Upgrade
|
Total Current Liabilities | 88,896 | 101,179 | 90,418 | 79,254 | 94,911 | Upgrade
|
Long-Term Debt | - | 975 | - | - | - | Upgrade
|
Total Liabilities | 88,896 | 102,154 | 90,418 | 79,254 | 94,911 | Upgrade
|
Common Stock | 214,999 | 214,999 | 86,000 | 86,000 | 86,000 | Upgrade
|
Additional Paid-In Capital | - | - | 97,659 | 97,659 | 97,659 | Upgrade
|
Retained Earnings | 303,881 | 253,473 | 233,791 | 182,591 | 162,789 | Upgrade
|
Shareholders' Equity | 518,881 | 468,472 | 417,450 | 366,250 | 346,448 | Upgrade
|
Total Liabilities & Equity | 607,777 | 570,626 | 507,868 | 445,504 | 441,359 | Upgrade
|
Total Debt | - | 7,775 | 5,230 | 3,528 | 5,378 | Upgrade
|
Net Cash (Debt) | 341,693 | 298,600 | 201,254 | 158,199 | 155,540 | Upgrade
|
Net Cash Growth | 14.43% | 48.37% | 27.22% | 1.71% | 2.97% | Upgrade
|
Net Cash Per Share | 15893.01 | 13887.88 | 8892.41 | 7358.34 | 7234.49 | Upgrade
|
Filing Date Shares Outstanding | 21.5 | 21.5 | 21.5 | 21.5 | 22.63 | Upgrade
|
Total Common Shares Outstanding | 21.5 | 21.5 | 21.5 | 21.5 | 22.63 | Upgrade
|
Working Capital | 344,430 | 282,572 | 219,768 | 176,192 | 159,900 | Upgrade
|
Book Value Per Share | 24134.06 | 21789.47 | 19416.28 | 17034.87 | 15308.18 | Upgrade
|
Tangible Book Value | 518,881 | 448,191 | 410,936 | 359,656 | 340,634 | Upgrade
|
Tangible Book Value Per Share | 24134.06 | 20846.14 | 19113.30 | 16728.17 | 15051.29 | Upgrade
|
Construction In Progress | 120 | 401.11 | 14,390 | 5,436 | 65,364 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.